RUNX1 and leukemia: Interestingly, preferentially expressed antigen of melanoma (PRAME) which has previously been shown to reduce tumorigenicity of leukemic cells in vivo, has also been shown to reduce expression of S100A4 [52], particularly in those leukemias associated with favorable outcome (e.g., in leukemia’s harboring RUNX1-ETO and PML-RARα).